The effect of a specific vitamin supplement containing L-methylfolate (Ocufolin forte) in patients with neovascular age-related macular degeneration
Patients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to ant...
Saved in:
| Published in | Advances in ophthalmology practice and research Vol. 5; no. 2; pp. 135 - 141 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.05.2025
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Patients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to antivascular endothelial growth factor (anti-VEGF) therapy reduces these two risk factors and favorably influences the disease course.
A total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8 mm above the intra-ocular pressure (IOP), and an IOP between 10 and 20 mmHg were included in this study. All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated. Fifteen patients additionally received one capsule of Ocufolin forte per day (Ocufolin group, OG), and the other twelve patients served as a control group (control group, CG). The following factors were measured before therapy and four months later: blood Hcy, best-corrected visual acuity (BCVA), IOP, RVP, optical coherence tomography (OCT), and optical coherence tomography - angiography (OCTA).
Hcy decreased on average by 5.58 μmol/L in the OG and by 0.57 μmol/L in the CG. The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG. The difference between the two groups was significant for both parameters (P <0.001); 66% of the OG and 41% of the CG had no retinal fluid at the end of the study. After the completion of the study, the injection intervals could be extended more often in the OG patients than in the CG patients.
When Ocufolin forte was added to the standard therapy, RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte. In addition, Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy. |
|---|---|
| AbstractList | Background: Patients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to antivascular endothelial growth factor (anti-VEGF) therapy reduces these two risk factors and favorably influences the disease course. Methods: A total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8 mm above the intra-ocular pressure (IOP), and an IOP between 10 and 20 mmHg were included in this study. All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated. Fifteen patients additionally received one capsule of Ocufolin forte per day (Ocufolin group, OG), and the other twelve patients served as a control group (control group, CG). The following factors were measured before therapy and four months later: blood Hcy, best-corrected visual acuity (BCVA), IOP, RVP, optical coherence tomography (OCT), and optical coherence tomography - angiography (OCTA). Results: Hcy decreased on average by 5.58 μmol/L in the OG and by 0.57 μmol/L in the CG. The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG. The difference between the two groups was significant for both parameters (P <0.001); 66% of the OG and 41% of the CG had no retinal fluid at the end of the study. After the completion of the study, the injection intervals could be extended more often in the OG patients than in the CG patients. Conclusions: When Ocufolin forte was added to the standard therapy, RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte. In addition, Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy. Patients with nAMD often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to anti-VEGF therapy reduces these two risk factors and favorably influences the disease course.BackgroundPatients with nAMD often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to anti-VEGF therapy reduces these two risk factors and favorably influences the disease course.A total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8 mm above the IOP, and an IOP between 10 and 20 mmHg were included in this study. All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated. Fifteen patients additionally received one capsule of Ocufolin forte per day (Ocufolin group, OG), and the other twelve patients served as a control group (control group, CG). The following factors were measured before therapy and four months later: blood Hcy, best-corrected visual acuity (BCVA), intra-ocular pressure (IOP), RVP, optical coherence tomography (OCT), and optical coherence tomography - angiography (OCTA).MethodsA total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8 mm above the IOP, and an IOP between 10 and 20 mmHg were included in this study. All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated. Fifteen patients additionally received one capsule of Ocufolin forte per day (Ocufolin group, OG), and the other twelve patients served as a control group (control group, CG). The following factors were measured before therapy and four months later: blood Hcy, best-corrected visual acuity (BCVA), intra-ocular pressure (IOP), RVP, optical coherence tomography (OCT), and optical coherence tomography - angiography (OCTA).Hcy decreased on average by 5.58 μmol/L in the OG and by 0.57 μmol/L in the CG. The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG. The difference between the two groups was significant for both parameters (P <0.001); 66% of the OG and 41% of the CG had no retinal fluid at the end of the study. After the completion of the study, the injection intervals could be extended more often in the OG patients than in the CG patients.ResultsHcy decreased on average by 5.58 μmol/L in the OG and by 0.57 μmol/L in the CG. The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG. The difference between the two groups was significant for both parameters (P <0.001); 66% of the OG and 41% of the CG had no retinal fluid at the end of the study. After the completion of the study, the injection intervals could be extended more often in the OG patients than in the CG patients.When Ocufolin forte was added to the standard therapy, RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte. In addition, Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy.ConclusionsWhen Ocufolin forte was added to the standard therapy, RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte. In addition, Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy. AbstractBackgroundPatients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to antivascular endothelial growth factor (anti-VEGF) therapy reduces these two risk factors and favorably influences the disease course. MethodsA total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8 mm above the intra-ocular pressure (IOP), and an IOP between 10 and 20 mmHg were included in this study. All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated. Fifteen patients additionally received one capsule of Ocufolin forte per day (Ocufolin group, OG), and the other twelve patients served as a control group (control group, CG). The following factors were measured before therapy and four months later: blood Hcy, best-corrected visual acuity (BCVA), IOP, RVP, optical coherence tomography (OCT), and optical coherence tomography - angiography (OCTA). ResultsHcy decreased on average by 5.58 μmol/L in the OG and by 0.57 μmol/L in the CG. The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG. The difference between the two groups was significant for both parameters ( P <0.001); 66% of the OG and 41% of the CG had no retinal fluid at the end of the study. After the completion of the study, the injection intervals could be extended more often in the OG patients than in the CG patients. ConclusionsWhen Ocufolin forte was added to the standard therapy, RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte. In addition, Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy. Patients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to antivascular endothelial growth factor (anti-VEGF) therapy reduces these two risk factors and favorably influences the disease course. A total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8 mm above the intra-ocular pressure (IOP), and an IOP between 10 and 20 mmHg were included in this study. All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated. Fifteen patients additionally received one capsule of Ocufolin forte per day (Ocufolin group, OG), and the other twelve patients served as a control group (control group, CG). The following factors were measured before therapy and four months later: blood Hcy, best-corrected visual acuity (BCVA), IOP, RVP, optical coherence tomography (OCT), and optical coherence tomography - angiography (OCTA). Hcy decreased on average by 5.58 μmol/L in the OG and by 0.57 μmol/L in the CG. The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG. The difference between the two groups was significant for both parameters (P <0.001); 66% of the OG and 41% of the CG had no retinal fluid at the end of the study. After the completion of the study, the injection intervals could be extended more often in the OG patients than in the CG patients. When Ocufolin forte was added to the standard therapy, RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte. In addition, Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy. Patients with nAMD often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate (Ocufolin forte) as an addition to anti-VEGF therapy reduces these two risk factors and favorably influences the disease course. A total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8 mm above the IOP, and an IOP between 10 and 20 mmHg were included in this study. All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated. Fifteen patients additionally received one capsule of Ocufolin forte per day (Ocufolin group, OG), and the other twelve patients served as a control group (control group, CG). The following factors were measured before therapy and four months later: blood Hcy, best-corrected visual acuity (BCVA), intra-ocular pressure (IOP), RVP, optical coherence tomography (OCT), and optical coherence tomography - angiography (OCTA). Hcy decreased on average by 5.58 μmol/L in the OG and by 0.57 μmol/L in the CG. The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG. The difference between the two groups was significant for both parameters ( <0.001); 66% of the OG and 41% of the CG had no retinal fluid at the end of the study. After the completion of the study, the injection intervals could be extended more often in the OG patients than in the CG patients. When Ocufolin forte was added to the standard therapy, RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte. In addition, Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy. |
| Author | Schötzau, Andreas Flammer, Josef Josifova, Tatjana Konieczka, Katarzyna |
| Author_xml | – sequence: 1 givenname: Tatjana surname: Josifova fullname: Josifova, Tatjana email: tjosifova@yahoo.com organization: Eye Clinic Orasis, Department for Medical and Surgical Retina, Reinach, Switzerland – sequence: 2 givenname: Katarzyna surname: Konieczka fullname: Konieczka, Katarzyna organization: Department of Ophthalmology, University of Basel, Switzerland – sequence: 3 givenname: Andreas surname: Schötzau fullname: Schötzau, Andreas organization: Statistical Consulting, University of Basel, Switzerland – sequence: 4 givenname: Josef surname: Flammer fullname: Flammer, Josef organization: Department of Ophthalmology, University of Basel, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40276027$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUstuFDEQHKEgEkJ-gAPyMRxmaXveCAWhiEeklXIgnK1eT3vXy8x4sD2L9j_4YDxsiBIk4GC5ZVdV2131NDka7EBJ8pzDggMvX20XaEe3ECCKBWQLAP4oORFlWaVZVYqje_Vxcub9FgBEzQEq8SQ5zkFUZVwnyY-bDTHSmlRgVjNkfiRltFFsZwL2ZmB-GseOehoCU3YIaAYzrNky7Sls9p22HQZi59dqimWEa-sCvWSxGjGYyPLsuwkbNpDdoVdTh47hmlJHM7FlPR7OWlrTQC5y7PAseayx83R2u58mXz68v7n8lC6vP15dvlumqqh5SBuVcYIVwmpVIIqKN21TadFiVlOpSCjIVY15XpdCcCrqvKgaqMpWtaVAEDw7Ta4Ouq3FrRyd6dHtpUUjfx1Yt5boglEdScjzvNVCV0LznESx4nVbl1mDVAPUeR213h60xmnVU6vizx12D0Qf3gxmI9d2J3m0EOqsigrntwrOfpvIB9kbr6jrMM5u8jLjTV4WWdkUEfrifrO7Lr99jQBxAChnvXek7yAc5JwfuZVzfuScHwmZjPmJpDcHEsWZ7ww56VV0UFFrXMxHHIr5N_3iD7qKgTAKu6-0J7-1kxuim5JLLyTIz3NA53yKAmb6_OjXfxf4X_efps34hQ |
| Cites_doi | 10.1161/CIRCULATIONAHA.106.612325 10.1016/S1054-8807(01)00095-3 10.1186/s40662-020-00199-y 10.1111/aos.13343 10.1186/s13167-015-0043-1 10.3945/jn.108.096404 10.3945/ajcn.112.057091 10.1016/j.mvr.2017.05.010 10.1016/j.cca.2015.09.007 10.3390/ijms241310790 10.3390/nu15214699 10.1007/s00417-014-2617-3 10.3390/ijms24021071 10.1001/jama.2023.26074 10.1016/j.survophthal.2007.08.005 10.1155/2014/768026 10.1055/s-2001-15902 10.1159/000520171 10.1016/j.mvr.2016.03.005 10.1016/j.preteyeres.2013.07.003 10.1016/j.arr.2009.06.002 10.3390/ijms252313053 10.1113/jphysiol.1995.sp020725 10.1073/pnas.0902072106 10.1016/S0140-6736(05)78717-1 10.1016/S1350-9462(02)00008-3 10.1016/j.ajpath.2017.11.009 10.1007/s00417-017-3647-4 10.1097/ICU.0b013e32833866ee 10.1136/bjo.2006.105338 10.1073/pnas.1424391112 10.1111/joim.13279 10.1016/j.dib.2018.09.070 10.1186/1471-2415-14-121 10.1186/s13167-015-0027-1 10.3390/nu14142821 |
| ContentType | Journal Article |
| Copyright | 2025 The Authors The Authors 2025 The Authors. 2025 The Authors 2025 |
| Copyright_xml | – notice: 2025 The Authors – notice: The Authors – notice: 2025 The Authors. – notice: 2025 The Authors 2025 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.aopr.2025.03.001 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2667-3762 |
| EndPage | 141 |
| ExternalDocumentID | oai_doaj_org_article_0444df2f72f14e25b18d8639ae800848 PMC12020837 40276027 10_1016_j_aopr_2025_03_001 S2667376225000137 1_s2_0_S2667376225000137 |
| Genre | Journal Article |
| GroupedDBID | .1- .FO 0R~ AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS FDB GROUPED_DOAJ M41 M~E OK1 PGMZT ROL RPM Z5R 6I. AAFTH AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c581t-9c31e0ba0bb5aa2719d97f2da38e6ce2c04c8a4486221e584579076dcd62a0213 |
| IEDL.DBID | DOA |
| ISSN | 2667-3762 |
| IngestDate | Wed Aug 27 01:26:28 EDT 2025 Thu Aug 21 18:26:51 EDT 2025 Wed Jul 02 04:49:32 EDT 2025 Mon Jul 21 05:51:40 EDT 2025 Thu Jul 03 08:38:27 EDT 2025 Sat Jun 28 18:17:59 EDT 2025 Thu Jun 19 21:30:46 EDT 2025 Tue Aug 26 16:31:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | OCT Anti-VEGF therapy OCTA Retinal venous pressure Neovascular age-related macular degeneration Ocufolin forte Homocysteine |
| Language | English |
| License | This is an open access article under the CC BY license. 2025 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c581t-9c31e0ba0bb5aa2719d97f2da38e6ce2c04c8a4486221e584579076dcd62a0213 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/0444df2f72f14e25b18d8639ae800848 |
| PMID | 40276027 |
| PQID | 3194653695 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0444df2f72f14e25b18d8639ae800848 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12020837 proquest_miscellaneous_3194653695 pubmed_primary_40276027 crossref_primary_10_1016_j_aopr_2025_03_001 elsevier_sciencedirect_doi_10_1016_j_aopr_2025_03_001 elsevier_clinicalkeyesjournals_1_s2_0_S2667376225000137 elsevier_clinicalkey_doi_10_1016_j_aopr_2025_03_001 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-05-01 |
| PublicationDateYYYYMMDD | 2025-05-01 |
| PublicationDate_xml | – month: 05 year: 2025 text: 2025-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Advances in ophthalmology practice and research |
| PublicationTitleAlternate | Adv Ophthalmol Pract Res |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Olli, Mikko, Salminen, Kaarniranta (bib7) 2009; 8 Flammer, Konieczka (bib8) 2015; 6 Mozaffarieh, Bärtschi, Henrich, Schoetzau, Flammer (bib13) 2014; 252 Firsching, Schütze, Motschmann, Behrens-Baumann, Meyer-Schwickerath (bib11) 1998; 351 Mahy, Tooke, Shore (bib18) 1995; 485 Lanzetta, Loewenstein (bib32) 2017; 255 Balaratnasingam, Morgan, Hazelton (bib40) 2007; 91 Huang, Wang, Sah (bib22) 2015; 5 Alrashdi, Deliyanti, Talia, Wilkinson-Berka (bib15) 2018; 188 Keenan, Agrón, Keane, Domalpally, Chew (bib27) 2024 Smith, Refsum (bib24) 2021; 290 Ardeljan, Chan (bib38) 2013; 37 Marchesi, Capierri, Pascale, Barbieri (bib30) 2024; 25 Shi, Wang, Airen (bib25) 2020; 7 Gopinath, Flood, Rochtchina, Wang, Mitchell (bib26) 2013; 98 Pellanda, Flammer, Haefliger (bib45) 2001; 218 Ajith (bib19) 2015; 450 (bib31) 2024 Kida, Flammer, Oku (bib42) 2018; 21 Fleckenstein, Steffen Schmitz-Valckenberg, Chakravarthy (bib1) 2024; 331 Samra, Zaidi, Rajpurohit (bib6) 2023; 24 Pizzorno (bib33) 2014; 4 Flammer, Orgül, Costa (bib9) 2002; 21 Schmidl, Howorka, Szegedi (bib28) 2020; 26 Bailey, Ayling (bib34) 2009; 106 Kalmbach, Choumenkovitch, Troen, Jacques, D'Agostino, Selhub (bib35) 2008; 138 Flammer (bib10) 2021 Foss, Rotsos, Empeslidis, Chong (bib4) 2022; 245 Toomey, Kelly, Saban, Bowes Rickman (bib2) 2015; 112 Washington, Robert, Liu (bib20) 2023; 24 Pinna, Zaccheddu, Boscia, Ciriaco, Solinas (bib5) 2018; 96 Fang, Baertschi, Mozaffarieh (bib14) 2014; 14 Antoniades, Shirodaria, Warrick (bib39) 2006; 114 Antoniades, Shirodaria, Warrick (bib43) 2006; 114 Blasiak, Petrovski, Veréb, Facskó, Kaarniranta (bib3) 2014; 2014 Cybulska-Heinrich, Baertschi, Loesche (bib12) 2015; 6 Merle, Barthes, Féart (bib23) 2022; 14 Fardous, Heydari (bib36) 2023; 15 Grieshaber, Flammer (bib16) 2007 Devogelaere, Schötzau (bib29) 2021; 3 Ruef, Moser, W Kübler, Bode (bib44) 2001; 10 Chen, Liu, Wang, Zhang, Liu, Su (bib41) 2017; 114 Pinna, Zaccheddu, Boscia, Carru, Solinas (bib21) 2018; 96 Krishnadev, Meleth, Chew (bib37) 2010; 21 Levine, Bebie (bib17) 2016; 106 Blasiak (10.1016/j.aopr.2025.03.001_bib3) 2014; 2014 Grieshaber (10.1016/j.aopr.2025.03.001_bib16) 2007 Antoniades (10.1016/j.aopr.2025.03.001_bib39) 2006; 114 Ajith (10.1016/j.aopr.2025.03.001_bib19) 2015; 450 Balaratnasingam (10.1016/j.aopr.2025.03.001_bib40) 2007; 91 Mozaffarieh (10.1016/j.aopr.2025.03.001_bib13) 2014; 252 Fleckenstein (10.1016/j.aopr.2025.03.001_bib1) 2024; 331 Huang (10.1016/j.aopr.2025.03.001_bib22) 2015; 5 Krishnadev (10.1016/j.aopr.2025.03.001_bib37) 2010; 21 (10.1016/j.aopr.2025.03.001_bib31) 2024 Gopinath (10.1016/j.aopr.2025.03.001_bib26) 2013; 98 Merle (10.1016/j.aopr.2025.03.001_bib23) 2022; 14 Kalmbach (10.1016/j.aopr.2025.03.001_bib35) 2008; 138 Pellanda (10.1016/j.aopr.2025.03.001_bib45) 2001; 218 Samra (10.1016/j.aopr.2025.03.001_bib6) 2023; 24 Shi (10.1016/j.aopr.2025.03.001_bib25) 2020; 7 Antoniades (10.1016/j.aopr.2025.03.001_bib43) 2006; 114 Flammer (10.1016/j.aopr.2025.03.001_bib8) 2015; 6 Cybulska-Heinrich (10.1016/j.aopr.2025.03.001_bib12) 2015; 6 Pizzorno (10.1016/j.aopr.2025.03.001_bib33) 2014; 4 Firsching (10.1016/j.aopr.2025.03.001_bib11) 1998; 351 Fardous (10.1016/j.aopr.2025.03.001_bib36) 2023; 15 Ruef (10.1016/j.aopr.2025.03.001_bib44) 2001; 10 Devogelaere (10.1016/j.aopr.2025.03.001_bib29) 2021; 3 Pinna (10.1016/j.aopr.2025.03.001_bib21) 2018; 96 Pinna (10.1016/j.aopr.2025.03.001_bib5) 2018; 96 Ardeljan (10.1016/j.aopr.2025.03.001_bib38) 2013; 37 Kida (10.1016/j.aopr.2025.03.001_bib42) 2018; 21 Lanzetta (10.1016/j.aopr.2025.03.001_bib32) 2017; 255 Marchesi (10.1016/j.aopr.2025.03.001_bib30) 2024; 25 Bailey (10.1016/j.aopr.2025.03.001_bib34) 2009; 106 Flammer (10.1016/j.aopr.2025.03.001_bib10) 2021 Fang (10.1016/j.aopr.2025.03.001_bib14) 2014; 14 Keenan (10.1016/j.aopr.2025.03.001_bib27) 2024 Flammer (10.1016/j.aopr.2025.03.001_bib9) 2002; 21 Washington (10.1016/j.aopr.2025.03.001_bib20) 2023; 24 Olli (10.1016/j.aopr.2025.03.001_bib7) 2009; 8 Smith (10.1016/j.aopr.2025.03.001_bib24) 2021; 290 Schmidl (10.1016/j.aopr.2025.03.001_bib28) 2020; 26 Toomey (10.1016/j.aopr.2025.03.001_bib2) 2015; 112 Levine (10.1016/j.aopr.2025.03.001_bib17) 2016; 106 Mahy (10.1016/j.aopr.2025.03.001_bib18) 1995; 485 Foss (10.1016/j.aopr.2025.03.001_bib4) 2022; 245 Alrashdi (10.1016/j.aopr.2025.03.001_bib15) 2018; 188 Chen (10.1016/j.aopr.2025.03.001_bib41) 2017; 114 |
| References_xml | – year: 2024 ident: bib27 article-title: Age-related eye disease study research group; age-related eye disease study 2 research group. Oral antioxidant and Lutein/Zeaxanthin supplements slow geographic atrophy progression to the fovea in age-related macular degeneration publication-title: Ophthalmology – volume: 24 start-page: 1071 year: 2023 ident: bib6 article-title: Warburg effect as a novel mechanism for homocysteine-induced features of age-related macular degeneration publication-title: Int J Mol Sci – volume: 351 start-page: 523 year: 1998 end-page: 524 ident: bib11 article-title: Non-invasive measurement of intracranial pressure publication-title: Lancet – volume: 485 start-page: 213 year: 1995 end-page: 219 ident: bib18 article-title: Capillary pressure during and after incremental venous pressure elevation in man publication-title: J Physiol. – volume: 4 start-page: 8 year: 2014 end-page: 14 ident: bib33 article-title: Homocysteine: friend or foe? publication-title: Integr Med – volume: 114 start-page: 1193 year: 2006 end-page: 1201 ident: bib39 article-title: 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling publication-title: Circulation – volume: 10 start-page: 311 year: 2001 end-page: 315 ident: bib44 article-title: Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells publication-title: Cardiovasc Pathol – volume: 255 start-page: 1259 year: 2017 end-page: 1273 ident: bib32 article-title: Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases publication-title: Graefes Arch Clin Exp Ophthalmol – volume: 8 start-page: 349 year: 2009 end-page: 358 ident: bib7 article-title: Regulatory role of HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD) publication-title: Ageing Res Rev – volume: 252 start-page: 1569 year: 2014 end-page: 1571 ident: bib13 article-title: Retinal venous pressure in the non-affected eye of patients with retinal vein occlusions publication-title: Graefes Arch Clin Exp Ophthalmol – volume: 21 start-page: 184 year: 2010 end-page: 189 ident: bib37 article-title: Nutritional supplements for age-related macular degeneration publication-title: Curr Opin Ophthalmol – volume: 450 start-page: 316 year: 2015 end-page: 321 ident: bib19 article-title: Ranimenon. Homocysteine in ocular diseases publication-title: Clin Chim Acta – volume: 138 start-page: 2323 year: 2008 end-page: 2327 ident: bib35 article-title: A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate publication-title: J Nutr – volume: 2014 year: 2014 ident: bib3 article-title: Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration publication-title: BioMed Res Int – volume: 188 start-page: 805 year: 2018 end-page: 817 ident: bib15 article-title: Endothelin-2 injures the blood-retinal barrier and macroglial Müller cells: interactions with angiotensin II, aldosterone, and NADPH oxidase publication-title: Am J Pathol – volume: 106 start-page: 67 year: 2016 end-page: 79 ident: bib17 article-title: Phase and amplitude of spontaneous retinal vein pulsations: an extended constant inflow and variable outflow model publication-title: Microvasc Res – volume: 7 start-page: 33 year: 2020 ident: bib25 article-title: Nutritional and medical food therapies for diabetic retinopathy publication-title: Eye Vis (Lond). – volume: 6 start-page: 5 year: 2015 ident: bib12 article-title: Patients with diabetic retinopathy have high retinal venous pressure publication-title: EPMA J – volume: 98 start-page: 129 year: 2013 end-page: 135 ident: bib26 article-title: Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration publication-title: Am J Clin Nutr – volume: 21 start-page: 59 year: 2018 end-page: 62 ident: bib42 article-title: Data on the involvement of endothelin-1 (ET-1) in the dysregulation of retinal veins publication-title: Data Brief – volume: 96 start-page: e269 year: 2018 end-page: e276 ident: bib5 article-title: Homocysteine and risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Acta Ophthalmol – volume: 6 start-page: 21 year: 2015 ident: bib8 article-title: Retinal venous pressure: the role of endothelin publication-title: EPMA J – volume: 112 start-page: E3040 year: 2015 end-page: E3049 ident: bib2 article-title: Regulation of age-related macular degeneration-like pathology by complement factor H publication-title: Proc Natl Acad Sci U S A – volume: 245 start-page: 204 year: 2022 end-page: 217 ident: bib4 article-title: Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment publication-title: Ophthalmologica – volume: 24 year: 2023 ident: bib20 article-title: Homocysteine and glaucoma publication-title: Int J Mol Sci – start-page: S115 year: 2007 end-page: S121 ident: bib16 article-title: Does the blood-brain barrier play a role in Glaucoma? publication-title: Surv Ophthalmol – volume: 96 start-page: e269 year: 2018 end-page: e276 ident: bib21 article-title: Homocysteine and risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Acta Ophthalmol – volume: 3 start-page: 54 year: 2021 end-page: 59 ident: bib29 article-title: The effects of vitamin supplementation containing L-methylfolate (Ocufolin® forte) on retinal venous pressure and homocysteine plasma levels in patients with glaucoma publication-title: hb TIMES Schw Aerztej – start-page: 60 year: 2021 end-page: 62 ident: bib10 article-title: Measuring and treating retinal venous pressure: effort and benefit publication-title: hb TIMES Schw Aerztej – volume: 5 year: 2015 ident: bib22 article-title: Homocysteine and the risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Sci Rep – volume: 331 start-page: 147 year: 2024 end-page: 157 ident: bib1 article-title: Age-related macular degeneration: a review publication-title: JAMA – volume: 14 start-page: 121 year: 2014 ident: bib14 article-title: The effect of flammer-syndrome on retinal venous pressure publication-title: BMC Ophthalmol – volume: 91 start-page: 441 year: 2007 end-page: 444 ident: bib40 article-title: Value of retinal vein pulsation characteristics in predicting increased optic disc excavation publication-title: Br J Ophthalmol – volume: 14 start-page: 2821 year: 2022 ident: bib23 article-title: B vitamins and incidence of advanced age-related macular degeneration: the alienor study publication-title: Nutrients – volume: 15 start-page: 4699 year: 2023 ident: bib36 article-title: Uncovering the hidden dangers and molecular mechanisms of excess folate: a narrative review publication-title: Nutrients – volume: 114 start-page: 1193 year: 2006 end-page: 1201 ident: bib43 article-title: 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling publication-title: Circulation – volume: 25 year: 2024 ident: bib30 article-title: Different therapeutic approaches for dry and wet AMD publication-title: Int J Mol Sci – volume: 106 start-page: 15424 year: 2009 end-page: 15429 ident: bib34 article-title: The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake publication-title: Proc Natl Acad Sci U S A. – volume: 114 start-page: 34 year: 2017 end-page: 40 ident: bib41 article-title: Homocysteine up-regulates endothelin type A receptor in vascular smooth muscle cells through Sirt1/ERK1/2 signaling pathway publication-title: Microvasc Res – volume: 218 start-page: 366 year: 2001 end-page: 369 ident: bib45 article-title: L-NAME- and U 46619-induced contractions in isolated porcine ciliary arteries versus vortex veins publication-title: Klin Monbl Augenheilkd – year: 2024 ident: bib31 article-title: _R: A Language and Environment for Statistical Computing_ – volume: 21 start-page: 359 year: 2002 end-page: 393 ident: bib9 article-title: The impact of ocular blood flow in glaucoma publication-title: Prog Retin Eye Res – volume: 26 start-page: 326 year: 2020 end-page: 333 ident: bib28 article-title: A pilot study to assess the effect of a three-month vitamin supplementation containing L-methylfolate on systemic homocysteine plasma concentrations and retinal blood flow in patients with diabetes publication-title: Mol Vis – volume: 37 start-page: 68 year: 2013 end-page: 89 ident: bib38 article-title: Aging is not a disease: distinguishing age-related macular degeneration from aging publication-title: Prog Retin Eye Res – volume: 290 start-page: 826 year: 2021 end-page: 854 ident: bib24 article-title: Homocysteine - from disease biomarker to disease prevention publication-title: J Intern Med – volume: 114 start-page: 1193 issue: 11 year: 2006 ident: 10.1016/j.aopr.2025.03.001_bib39 article-title: 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.612325 – year: 2024 ident: 10.1016/j.aopr.2025.03.001_bib31 – volume: 10 start-page: 311 issue: 6 year: 2001 ident: 10.1016/j.aopr.2025.03.001_bib44 article-title: Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells publication-title: Cardiovasc Pathol doi: 10.1016/S1054-8807(01)00095-3 – volume: 7 start-page: 33 year: 2020 ident: 10.1016/j.aopr.2025.03.001_bib25 article-title: Nutritional and medical food therapies for diabetic retinopathy publication-title: Eye Vis (Lond). doi: 10.1186/s40662-020-00199-y – volume: 96 start-page: e269 issue: 3 year: 2018 ident: 10.1016/j.aopr.2025.03.001_bib5 article-title: Homocysteine and risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Acta Ophthalmol doi: 10.1111/aos.13343 – volume: 6 start-page: 21 year: 2015 ident: 10.1016/j.aopr.2025.03.001_bib8 article-title: Retinal venous pressure: the role of endothelin publication-title: EPMA J doi: 10.1186/s13167-015-0043-1 – volume: 138 start-page: 2323 issue: 12 year: 2008 ident: 10.1016/j.aopr.2025.03.001_bib35 article-title: A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate publication-title: J Nutr doi: 10.3945/jn.108.096404 – start-page: 60 issue: 3 year: 2021 ident: 10.1016/j.aopr.2025.03.001_bib10 article-title: Measuring and treating retinal venous pressure: effort and benefit publication-title: hb TIMES Schw Aerztej – volume: 3 start-page: 54 issue: 3 year: 2021 ident: 10.1016/j.aopr.2025.03.001_bib29 article-title: The effects of vitamin supplementation containing L-methylfolate (Ocufolin® forte) on retinal venous pressure and homocysteine plasma levels in patients with glaucoma publication-title: hb TIMES Schw Aerztej – volume: 98 start-page: 129 issue: 1 year: 2013 ident: 10.1016/j.aopr.2025.03.001_bib26 article-title: Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration publication-title: Am J Clin Nutr doi: 10.3945/ajcn.112.057091 – volume: 114 start-page: 34 year: 2017 ident: 10.1016/j.aopr.2025.03.001_bib41 article-title: Homocysteine up-regulates endothelin type A receptor in vascular smooth muscle cells through Sirt1/ERK1/2 signaling pathway publication-title: Microvasc Res doi: 10.1016/j.mvr.2017.05.010 – volume: 450 start-page: 316 year: 2015 ident: 10.1016/j.aopr.2025.03.001_bib19 article-title: Ranimenon. Homocysteine in ocular diseases publication-title: Clin Chim Acta doi: 10.1016/j.cca.2015.09.007 – volume: 24 issue: 13 year: 2023 ident: 10.1016/j.aopr.2025.03.001_bib20 article-title: Homocysteine and glaucoma publication-title: Int J Mol Sci doi: 10.3390/ijms241310790 – volume: 15 start-page: 4699 issue: 21 year: 2023 ident: 10.1016/j.aopr.2025.03.001_bib36 article-title: Uncovering the hidden dangers and molecular mechanisms of excess folate: a narrative review publication-title: Nutrients doi: 10.3390/nu15214699 – volume: 252 start-page: 1569 issue: 10 year: 2014 ident: 10.1016/j.aopr.2025.03.001_bib13 article-title: Retinal venous pressure in the non-affected eye of patients with retinal vein occlusions publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-014-2617-3 – volume: 24 start-page: 1071 issue: 2 year: 2023 ident: 10.1016/j.aopr.2025.03.001_bib6 article-title: Warburg effect as a novel mechanism for homocysteine-induced features of age-related macular degeneration publication-title: Int J Mol Sci doi: 10.3390/ijms24021071 – volume: 4 start-page: 8 year: 2014 ident: 10.1016/j.aopr.2025.03.001_bib33 article-title: Homocysteine: friend or foe? publication-title: Integr Med – volume: 331 start-page: 147 issue: 2 year: 2024 ident: 10.1016/j.aopr.2025.03.001_bib1 article-title: Age-related macular degeneration: a review publication-title: JAMA doi: 10.1001/jama.2023.26074 – volume: 114 start-page: 1193 issue: 11 year: 2006 ident: 10.1016/j.aopr.2025.03.001_bib43 article-title: 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.612325 – start-page: S115 year: 2007 ident: 10.1016/j.aopr.2025.03.001_bib16 article-title: Does the blood-brain barrier play a role in Glaucoma? publication-title: Surv Ophthalmol doi: 10.1016/j.survophthal.2007.08.005 – volume: 2014 year: 2014 ident: 10.1016/j.aopr.2025.03.001_bib3 article-title: Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration publication-title: BioMed Res Int doi: 10.1155/2014/768026 – volume: 218 start-page: 366 issue: 5 year: 2001 ident: 10.1016/j.aopr.2025.03.001_bib45 article-title: L-NAME- and U 46619-induced contractions in isolated porcine ciliary arteries versus vortex veins publication-title: Klin Monbl Augenheilkd doi: 10.1055/s-2001-15902 – volume: 245 start-page: 204 issue: 3 year: 2022 ident: 10.1016/j.aopr.2025.03.001_bib4 article-title: Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment publication-title: Ophthalmologica doi: 10.1159/000520171 – volume: 106 start-page: 67 year: 2016 ident: 10.1016/j.aopr.2025.03.001_bib17 article-title: Phase and amplitude of spontaneous retinal vein pulsations: an extended constant inflow and variable outflow model publication-title: Microvasc Res doi: 10.1016/j.mvr.2016.03.005 – volume: 37 start-page: 68 year: 2013 ident: 10.1016/j.aopr.2025.03.001_bib38 article-title: Aging is not a disease: distinguishing age-related macular degeneration from aging publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2013.07.003 – volume: 26 start-page: 326 year: 2020 ident: 10.1016/j.aopr.2025.03.001_bib28 article-title: A pilot study to assess the effect of a three-month vitamin supplementation containing L-methylfolate on systemic homocysteine plasma concentrations and retinal blood flow in patients with diabetes publication-title: Mol Vis – volume: 8 start-page: 349 issue: 4 year: 2009 ident: 10.1016/j.aopr.2025.03.001_bib7 article-title: Regulatory role of HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD) publication-title: Ageing Res Rev doi: 10.1016/j.arr.2009.06.002 – volume: 25 issue: 23 year: 2024 ident: 10.1016/j.aopr.2025.03.001_bib30 article-title: Different therapeutic approaches for dry and wet AMD publication-title: Int J Mol Sci doi: 10.3390/ijms252313053 – volume: 485 start-page: 213 issue: Pt 1 year: 1995 ident: 10.1016/j.aopr.2025.03.001_bib18 article-title: Capillary pressure during and after incremental venous pressure elevation in man publication-title: J Physiol. doi: 10.1113/jphysiol.1995.sp020725 – volume: 106 start-page: 15424 issue: 36 year: 2009 ident: 10.1016/j.aopr.2025.03.001_bib34 article-title: The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake publication-title: Proc Natl Acad Sci U S A. doi: 10.1073/pnas.0902072106 – volume: 351 start-page: 523 issue: 9101 year: 1998 ident: 10.1016/j.aopr.2025.03.001_bib11 article-title: Non-invasive measurement of intracranial pressure publication-title: Lancet doi: 10.1016/S0140-6736(05)78717-1 – volume: 21 start-page: 359 issue: 4 year: 2002 ident: 10.1016/j.aopr.2025.03.001_bib9 article-title: The impact of ocular blood flow in glaucoma publication-title: Prog Retin Eye Res doi: 10.1016/S1350-9462(02)00008-3 – year: 2024 ident: 10.1016/j.aopr.2025.03.001_bib27 article-title: Age-related eye disease study research group; age-related eye disease study 2 research group. Oral antioxidant and Lutein/Zeaxanthin supplements slow geographic atrophy progression to the fovea in age-related macular degeneration publication-title: Ophthalmology – volume: 188 start-page: 805 issue: 3 year: 2018 ident: 10.1016/j.aopr.2025.03.001_bib15 article-title: Endothelin-2 injures the blood-retinal barrier and macroglial Müller cells: interactions with angiotensin II, aldosterone, and NADPH oxidase publication-title: Am J Pathol doi: 10.1016/j.ajpath.2017.11.009 – volume: 255 start-page: 1259 issue: 7 year: 2017 ident: 10.1016/j.aopr.2025.03.001_bib32 article-title: Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-017-3647-4 – volume: 21 start-page: 184 issue: 3 year: 2010 ident: 10.1016/j.aopr.2025.03.001_bib37 article-title: Nutritional supplements for age-related macular degeneration publication-title: Curr Opin Ophthalmol doi: 10.1097/ICU.0b013e32833866ee – volume: 91 start-page: 441 issue: 4 year: 2007 ident: 10.1016/j.aopr.2025.03.001_bib40 article-title: Value of retinal vein pulsation characteristics in predicting increased optic disc excavation publication-title: Br J Ophthalmol doi: 10.1136/bjo.2006.105338 – volume: 112 start-page: E3040 issue: 23 year: 2015 ident: 10.1016/j.aopr.2025.03.001_bib2 article-title: Regulation of age-related macular degeneration-like pathology by complement factor H publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1424391112 – volume: 290 start-page: 826 issue: 4 year: 2021 ident: 10.1016/j.aopr.2025.03.001_bib24 article-title: Homocysteine - from disease biomarker to disease prevention publication-title: J Intern Med doi: 10.1111/joim.13279 – volume: 21 start-page: 59 year: 2018 ident: 10.1016/j.aopr.2025.03.001_bib42 article-title: Data on the involvement of endothelin-1 (ET-1) in the dysregulation of retinal veins publication-title: Data Brief doi: 10.1016/j.dib.2018.09.070 – volume: 14 start-page: 121 year: 2014 ident: 10.1016/j.aopr.2025.03.001_bib14 article-title: The effect of flammer-syndrome on retinal venous pressure publication-title: BMC Ophthalmol doi: 10.1186/1471-2415-14-121 – volume: 6 start-page: 5 issue: 1 year: 2015 ident: 10.1016/j.aopr.2025.03.001_bib12 article-title: Patients with diabetic retinopathy have high retinal venous pressure publication-title: EPMA J doi: 10.1186/s13167-015-0027-1 – volume: 96 start-page: e269 issue: 3 year: 2018 ident: 10.1016/j.aopr.2025.03.001_bib21 article-title: Homocysteine and risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Acta Ophthalmol doi: 10.1111/aos.13343 – volume: 5 year: 2015 ident: 10.1016/j.aopr.2025.03.001_bib22 article-title: Homocysteine and the risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Sci Rep – volume: 14 start-page: 2821 issue: 14 year: 2022 ident: 10.1016/j.aopr.2025.03.001_bib23 article-title: B vitamins and incidence of advanced age-related macular degeneration: the alienor study publication-title: Nutrients doi: 10.3390/nu14142821 |
| SSID | ssj0002810072 |
| Score | 2.3039758 |
| Snippet | Patients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure... AbstractBackgroundPatients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal... Patients with nAMD often have pathologically elevated homocysteine (Hcy) and increased retinal venous pressure (RVP). We tested whether the administration of a... Background: Patients with neovascular age-related macular degeneration (nAMD) often have pathologically elevated homocysteine (Hcy) and increased retinal... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 135 |
| SubjectTerms | Anti-VEGF therapy Full Length Homocysteine Neovascular age-related macular degeneration OCT OCTA Ocufolin forte Ophthalmology Retinal venous pressure |
| Title | The effect of a specific vitamin supplement containing L-methylfolate (Ocufolin forte) in patients with neovascular age-related macular degeneration |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2667376225000137 https://www.clinicalkey.es/playcontent/1-s2.0-S2667376225000137 https://dx.doi.org/10.1016/j.aopr.2025.03.001 https://www.ncbi.nlm.nih.gov/pubmed/40276027 https://www.proquest.com/docview/3194653695 https://pubmed.ncbi.nlm.nih.gov/PMC12020837 https://doaj.org/article/0444df2f72f14e25b18d8639ae800848 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k14VEbiAEIRsWPHyREQVYUoHKBSb5afsFWbrUgWif_BD2bGTlYbQPTCYaUom2yynrHns_3NN4Q8dUa1ofJd2UlrS8D_bWmsiKXrjGPGiagUJjgffWgOj8W7E3myU-oLOWFZHjg33EvUM_ORR8UjE4FLy1rfQlg1oU1a8Dj6QszbmUydpiUj3P3nU5ZMJnSZ9QUKgHKZVU3ZIhIlwf5FQPoTcP7Om9wJRAc3yPUJQdJX-c1vkiuhv0WuHk175LfJT7A8zTQNuo7UUEymREIQ_b4azfmqpwNW8kzLghSZ6rlGBH1fYjXpH2cRJrtjoM8-uk3Eij40Ih_3OYWjSYR1oLh6S_uw5bFSGJXKlBYTPD03-ZwPX5KmNZr-Djk-ePv5zWE51V4onWzZWHauZqGyprJWGsMV63ynIvembgMWEXOVcK0B2zacswAoRiqYZjfe-YYbwA31XbLXr_twn1AWvfAIPBoLc5eqMTAD9JWykikrmPAFeTHbQV9kiQ09c89ONVpNo9V0VSMBryCv0VTbK1EeO50Ap9GT0-jLnKYg9WxoPWegwpgJP7T656PV3-4Kw9TtB830wHWlP3EspgphhsuEsVVB5PbOCdlkxHLpE5_MXqih2-NejgHjbgYNIycq4zWdLMi97JXbJhEVVw18CtIu_HXRZstv-tXXJC3OOBZtrdWD_9HKD8k1_C-ZHvqI7I3fNuExQLjR7qfeup_W1n4BHcRGvw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+a+specific+vitamin+supplement+containing+L-methylfolate+%28Ocufolin+forte%29+in+patients+with+neovascular+age-related+macular+degeneration&rft.jtitle=Advances+in+ophthalmology+practice+and+research&rft.au=Josifova%2C+Tatjana&rft.au=Konieczka%2C+Katarzyna&rft.au=Sch%C3%B6tzau%2C+Andreas&rft.au=Flammer%2C+Josef&rft.date=2025-05-01&rft.issn=2667-3762&rft.eissn=2667-3762&rft.volume=5&rft.issue=2&rft.spage=135&rft.epage=141&rft_id=info:doi/10.1016%2Fj.aopr.2025.03.001&rft.externalDBID=ECK1-s2.0-S2667376225000137&rft.externalDocID=1_s2_0_S2667376225000137 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26673762%2FS2667376225X00020%2Fcov150h.gif |